medigraphic.com
ISSN 0188-9796 (Print)

2004, Number 3

<< Back Next >>

Rev Endocrinol Nutr 2004; 12 (3)

The metabolic syndrome. Characteristics of the metabolic syndrome in Mexico Position of the Sociedad Mexicana de Nutrición y Endocrinología about definition, physiopathology and diagnostic

Lerman GI, Aguilar-Salinas CA, Gómez-Pérez FJ, Reza AA, Hernández JS, Vázquez CC, Rull JA

Language: Spanish
References: 61
Page: 109-122
PDF size: 138.87 Kb.


Text Extraction

No abstract


REFERENCES

  1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.

  2. Groop L, Orho-Melander M. The dysmetabolic syndrome. J Intern Med 2001; 250: 105-120.

  3. Ford ES, Giles WH, Diez WH. Prevalence of the metabolic syndrome among US adults. Findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.

  4. Lebovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes 2001; 109(Suppl 2): S135-S148.

  5. De Fronzo RA, Ferrannini E. Insulin resistance. A multifactorial syndrome responsible for NIDDM, obesity, hypertension, dislipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.

  6. Olefsky J. Insulin resistance. In: Ellenberg & Rifkin’s (eds). Diabetes mellitus. 5th ed. Appleton & Lange 1997: 513-552.

  7. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453-458.

  8. Yanovski S, Yanovski J. Obesity. N Engl J Med 2002; 346: 591-602.

  9. Beck-Nielsen H, Groop LC. Metabolic and genetic characterization of prediabetic states. J Clin Invest 1994; 94: 1714-1721.

  10. Laws A, Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentration. J Int Med 1992; 231: 25-30.

  11. Sanyal AJ, Campbell-Sargent C, Mirashi F et al. Nonalcoholic steatohepatitis. Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-1192.

  12. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and complications for pathogenesis. Endocr Rev 1997; 18: 774-800.

  13. Facchini FS , Stoohs A, Reaven GM. Enhanced sympathetic nervous system activity. The relationship between insulin resistance, hyperinsulinemia and heart rate. Am J Hypertension 1996; 9: 1013-1017.

  14. Miegs JB, Mittleman MA, Nathan DM. Hyperinsulinemia, hyperglycemia, and impaired homentostasis. The Framingham Offspring Study. JAMA 2000; 283: 221-228.

  15. Sakkinen P, Wahl P, Cushman M, Lewis M, Tracy R. Clustering of procoagulation, inflammation and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000; 152: 897-907.

  16. Chen N-G, Holmes M, Reaven GM. Relationship between insulin resistance, soluble adhesion molecules, and mononuclear cell binding in healthy volunteers. J Clin Endocrinol Metab 1999; 84: 3485-3489.

  17. Després IP, Marette A. Relation of components of insulin resistance syndrome to coronary disease risk. Curr Op Lipidol 1994; 5: 274-289.

  18. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46: 3-10.

  19. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000: 106; 473-481.

  20. DeFronzo R, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and ASCVD. Diabetes Care Rev 1991; 14: 173-194.

  21. Methews DR, Hosker JP, Rudensky AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985; 28: 412-419.

  22. Haffner SM, Kennedy E, Gonzalez C, Stern MP, Miettinen H. A prospective analysis of the HOMA model: the Mexico City Diabetes Study. Diabetes Care 1996; 19: 1138-1141.

  23. Matsuda M, DeFronzo R. Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 1999; 22: 1462-1470.

  24. Cederholm J, Wibell L. Insulin release and peripheral sensitivity at the oral glucose tolerance test. Diabetes Res Clin Pract 1990; 10: 167-175.

  25. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Järvinen H, Van Haeften T, Renn W, Gerich J. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000; 23: 295-301.

  26. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity Check index: a simple accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-2410.

  27. Caro J. Insulin resistance in obese and nonobese man. J Clin Endocrinol Metab 1991; 73: 691-696.

  28. American Diabetes Association. Consensus Development Conference on Insulin Resistance. Diabetes Care 1998; 21: 310-314.

  29. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M. Prevalence of insulin resistance in metabolic disorders, The Bruneck Study. Diabetes 1998; 47: 1643-1649.

  30. Aguilar-Salinas CA, Rojas R, Gomez-Perez FJ, Garcia E, Valles V, Rios-Torres JM, Franco A, Olaiz G, Sepulveda J, Rull JA. Prevalence and characteristics of early-onset type 2 diabetes in Mexico. Am J Med 2002; 113: 569-574.

  31. Lerman I, Villa AR, Ríos JM, Tamez LE, Gomez PFJ, Luna VS, Rull JA. Correlations between surrogate measures of insulin resistance and cardiovascular risk factors in obese and overweight patients. J of Diabetes and its Complications 2003; 17: 66-72.

  32. McLaughin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003; 139: 802-809.

  33. Belfiore F, Iannello S, Volpicelli G. Insulin sensitivity indices calculated from basal and OGTT induced insulin, glucose, and FFA levels. Mol Gen Metab 1988; 63: 134-141.

  34. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957.

  35. Lindahl B, Asplund K, Hallmans G. High serum insulin, insulin resistance and their associations with cardiovascular risk factors The Northen Sweden MONICA population study. J Intern Med 1993; 234: 263-270.

  36. Modan M, Halkin H, Almong S, Lusky A, Eshkol A, Shelfi M, Shitris A, Fuch Z. Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest 1985; 75: 809-817.

  37. Vázquez ChC, Salinas OS, Gómez DRA, Rosso JMM, Jiménez VM, Argüero SR. Niveles de insulina y factores de riesgo cardiovascular en mexicanos hipertensos versus normotensos. Rev Endocrin y Nutrición 2003; 11: 7-14.

  38. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonals JM, Parrot M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clinical Chemistry 2002; 48: 436-472.

  39. World Health Organization: Definition Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Geneva, World Health Org. 1999.

  40. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high cholesterol. JAMA 2001; 285: 2486-2497.

  41. Balkau B, Charles MA, Drivsholm T, Borch-Jhonsen K, Wareham N, Yudkin JS, Morris R, Zavaroni I, van Dam R, Feskins E, Gabriel R, Diet M, Nilsson P, Hedblad B. European Group for the Study of Insulin Resistance (EGIR): Frequency of the WHO metabolic syndrome in European cohorts, and the alternative definition of an insulin resistance syndrome. Diabetes Metab 2002; 28: 364-376.

  42. Bloomgarden ZT. American Association of clinical Endocrinologists (AACE) Consensus Conference on the Insulin Resistance Syndrome, 25-26 August 2002, Washington, DC. Diabetes Care 2003; 26: 1297-1303.

  43. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 2003; 26: 575-581.

  44. Meigs JB. Epidemiology of the Metabolic Syndrome 2002. Am J Managed Care 2002; 8: 5283-5292.

  45. Grundy SM, Brewer B, Cleeman J, Smith SC, Lenfant C. Definition of Metabolic Syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004; 109: 433-438.

  46. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relationship between several surrogare estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy, nondiabetic volunteers. Diabetes Care 2000; 23: 171-175.

  47. Aguilar SC, Rojas R, Gomez PFJ, Valles V, Franco A, Olaiz G, Rull JA, Sepúlveda J. The prevalence of metabolic syndrome in Mexico. Arch Medical Res 2004; 35: 76-81.

  48. The Expert committee on the diagnosis and classification of diabetes mellitus: follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167.

  49. Harris SB, Zinman B. Primary prevention of type 2 diabetes in high-risk populations. Diabetes Care 2000; 23: 879-881.

  50. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Diabetes Prevention Program Research Group. N Engl J Med 2002; 34: 393-403.

  51. Tsui EYL, Zinman B. Exercise and diabetes: new insights and therapeutic goals. The Endocrinologist 1995; 5: 263-271.

  52. American Diabetes Association and National Institute of Diabetes, Digestive an Kidney Diseases: The prevention of type 2 diabetes. Diabetes Care 2002; 25: 742-749.

  53. Facchini F, Hua N, Abbasi F, Reaven G. Insulin resistance as a predictor of age related disease. J Clin Endoc Metab 2001; 86: 3574-3578.

  54. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin resistance syndrome (syndrome X). Diabetes 1992; 41: 715-722.

  55. Edelstein SL, Knowler WC, Brain RP, Andres R, Barret-Connor EL, Dowse GK, Haffner SM, Pettit DJ, Sorkin JD, Muller DC, Collins VR, Hamman RF. Predictors of progression from impaired glucose tolerance to NIDDM; an analysis of six prospective studies. Diabetes 1997; 46: 701-710.

  56. Ferrannini E, Natali A, Bell P, Cavallo-Perin, Lalic N, Mingrone G. On behalf of the European Group for the Study of Insulin Resistance. Insulin resistance and hypersecretion in obesity. J Clin Invest 1997; 1: 1166-1173.

  57. Alexander ChM, Landsman PB, Teutsch SM, Haffner SM. NCEP- defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 1210-1214.

  58. Isomaa BO, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.

  59. Meigs JB. The metabolic syndrome: may be a guidepost or detour to preventing type 2 diabetes and cardiovascular disease. (editorial) BMJ 2003; 327: 61-62.

  60. Yip J, Facchini FS, Reaven GM. Resistance to insulin mediated glucose disposal a predictor of cardiovascular disease. J Clin Endocrinol Metab 1998; 83: 2773-2776.

  61. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997; 20: 1087-1092.




2020     |     www.medigraphic.com